Lori Tierney.

JACKSONVILLE,  Fla.—Johnson & Johnson Vision has named Lori Tierney as president, Americas. In this critical leadership role, Tierney will have full accountability for shaping the strategy and driving industry-leading growth of the vision care portfolio in both North America and Latin America (LATAM). Under her leadership, she will be responsible for world-leading brands such as Acuvue contact lenses, the company said in a statement. Tierney takes over the position from Thomas Swinnen, who was named Strategic Customer Officer, Johnson & Johnson MedTech, U.S. in July, 2022. Based in Philadelphia, Pa., she will operate from the company's Jacksonville, Fla. headquarters.

Tierney has more than 20 years of broad health care industry experience and a strong track record of success in leading end-to-end businesses, including operational and innovation excellence, with a focus on developing high-performing diverse teams.
“I’m so inspired by the ingenuity and passion of our Johnson & Johnson Vision teams’ continued commitment to raising the standard of eye health around the world,” said Tierney. “As a leader with a relentless focus on patients, I’m so proud to be a part of this journey to elevate and advance healthy sight for all.”
Tierney brings deep experience across multiple sectors in health care, including health information technology solutions, medtech, biopharmaceuticals, and medical devices & diagnostics. She has a long tenure of success within Johnson & Johnson, most recently serving as worldwide president for Mentor. She also led Johnson & Johnson’s One Medical Device enterprise strategy and commercial operations. In this role, she shaped the commercial capabilities in North America to support the product portfolio across specialty care for Depuy Synthes Orthopedics, Biosense Webster Cardiovascular, Cerenovus Neurovascular Specialty Surgery, and Ethicon.
Prior to her success at Johnson & Johnson, Tierney held notable leadership roles with increasing responsibility at AstraZenca, Endo Pharmaceuticals, and Centocor, which was later acquired by Johnson & Johnson.